Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.

作者信息

Hou Peng, Liu Dingxie, Xing Mingzhao

出版信息

Cell Cycle. 2007 Feb 1;6(3):377-9. doi: 10.4161/cc.6.3.3818. Epub 2007 Feb 5.

DOI:10.4161/cc.6.3.3818

PMID:17297294

Abstract

摘要

相似文献

Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.

Cell Cycle. 2007 Feb 1;6(3):377-9. doi: 10.4161/cc.6.3.3818. Epub 2007 Feb 5.

Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.

J Pathol. 2009 Apr;217(5):707-15. doi: 10.1002/path.2496.

Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma.

Oncogene. 2006 Jul 13;25(30):4235-40. doi: 10.1038/sj.onc.1209448. Epub 2006 Feb 27.

Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.

Mol Cancer Ther. 2007 Mar;6(3):1070-8. doi: 10.1158/1535-7163.MCT-06-0449.

BRAF is a therapeutic target in aggressive thyroid carcinoma.

Clin Cancer Res. 2006 Mar 1;12(5):1623-9. doi: 10.1158/1078-0432.CCR-05-2378.

BRAF in papillary thyroid carcinoma.

Cell Oncol. 2007;29(4):269-77. doi: 10.1155/2007/489604.

ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues.

Endocr Res. 2013;38(2):89-97. doi: 10.3109/07435800.2012.723292.

Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.

Clin Cancer Res. 2007 Feb 15;13(4):1341-9. doi: 10.1158/1078-0432.CCR-06-1753.

Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.

J Clin Endocrinol Metab. 2013 May;98(5):E934-42. doi: 10.1210/jc.2012-3930. Epub 2013 Mar 26.

Cancer: Small papillary thyroid cancers--is BRAF of prognostic value?

Nat Rev Endocrinol. 2011 Jan;7(1):9-10. doi: 10.1038/nrendo.2010.213.

引用本文的文献

Treatment outcome of NSCLC patients with BRAF mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany.

ESMO Open. 2025 Jul 14;10(8):105124. doi: 10.1016/j.esmoop.2025.105124.

Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations.

Innovation (Camb). 2024 Oct 18;5(6):100661. doi: 10.1016/j.xinn.2024.100661. eCollection 2024 Nov 4.

and Thyroid Tumors.

Cancers (Basel). 2021 Jul 30;13(15):3834. doi: 10.3390/cancers13153834.

Actionable FGFR1 and BRAF mutations in adult circumscribed gliomas.

J Neurooncol. 2019 Nov;145(2):241-245. doi: 10.1007/s11060-019-03306-9. Epub 2019 Oct 31.

SOX11 expression in a case of papillary thyroid carcinoma with fibromatosis/fasciitis-like stroma containing BRAF c.1799_1801delTGA and CTNNB1 c.133T>C mutations.

Virchows Arch. 2019 Oct;475(4):519-525. doi: 10.1007/s00428-019-02619-4. Epub 2019 Jul 20.

[BRAF gene mutations in ameloblastic fibromas].

Beijing Da Xue Xue Bao Yi Xue Ban. 2019 Feb 18;51(1):4-8. doi: 10.19723/j.issn.1671-167X.2019.01.002.

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.

Drug Des Devel Ther. 2016 Feb 29;10:873-84. doi: 10.2147/DDDT.S93459. eCollection 2016.

Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population.

Arch Pathol Lab Med. 2016 Feb;140(2):134-9. doi: 10.5858/arpa.2014-0612-OA.

A 3-bp Deletion VK600-1E in the BRAF Gene Detected in a Young Woman with Papillary Thyroid Carcinoma.

Endocr Pathol. 2015 Dec;26(4):309-14. doi: 10.1007/s12022-015-9387-2.

BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib.

Int J Clin Exp Pathol. 2015 Mar 1;8(3):3294-8. eCollection 2015.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验